Imunon, Inc. (NasdaqCM:IMNN) Stock Price & Quote Analysis

IMNN Stock Overview

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.

IMNN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 66.21% per year

Risk Analysis

Makes less than USD$1m in revenue ($500K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($12M)

My Notes

New

Notes are coming soon

Imunon, Inc. Competitors

TC Biopharm (Holdings)

NasdaqCM:TCBP

US$12.9m

Yubo International Biotech

OTCPK:YBGJ

US$10.5m

OpGen

NasdaqCM:OPGN

US$10.1m

Bellicum Pharmaceuticals

NasdaqCM:BLCM

US$11.0m

Price History & Performance

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share Price	US$1.60
52 Week High	US$7.68
52 Week Low	US$1.26
Beta	2.05
1 Month Change	-0.62%
3 Month Change	3.23%
1 Year Change	-74.81%
3 Year Change	-92.33%
5 Year Change	-94.97%
Change since IPO	-99.99%

Celsion changes name to Imunon (IMNN)

Sep 19

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Shareholder Returns

	IMNN	US Biotechs	US Market
7D	2.6%	-0.8%	1.7%
1Y	-74.8%	4.4%	-9.6%

Return vs Industry: IMNN underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: IMNN underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	7.8%
Biotechs Industry Average Movement	12.1%
Market Average Movement	6.7%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	2.8%

Stable Share Price: IMNN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: IMNN's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1982	29	Corinne Le Goff	https://www.imunon.com

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
IMNN fundamental statistics
Market Cap	US$11.89m
Earnings (TTM)	-US$26.89m
Revenue (TTM)	US$500.00k

23.8x

P/S Ratio

-0.4x

P/E Ratio

Is IMNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMNN income statement (TTM)
Revenue	US$500.00k
Cost of Revenue	US$11.72m
Gross Profit	-US$11.22m
Other Expenses	US$15.67m
Earnings	-US$26.89m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.62
Gross Margin	-2,243.33%
Net Profit Margin	-5,377.37%
Debt/Equity Ratio	14.5%

How did IMNN perform over the long term?

See historical performance and comparison

IMNN Stock Overview

Rewards

Risk Analysis

Imunon, Inc. Competitors

NasdaqCM:TCBP

US$12.9m

OTCPK:YBGJ

US$10.5m

NasdaqCM:OPGN

US$10.1m

NasdaqCM:BLCM

US$11.0m

Price History & Performance

Recent News & Updates

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Recent updates

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019)

Celsion Corporation Announces Update on Phase I/II Ovation 2 Study

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (Nol) Program

Price target raised to US$4.00

Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Formation of Vaccine Advisory Board

New 90-day high: US$2.22

Celsion Corporation Files Provisional U.S. Patent Application for A Broad Range of Next Generation DNA Vaccines

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $34.999999 million.

New 90-day high: US$1.28

New 90-day high: US$0.80

Celsion Corporation Announces the Retirement of Dr. Alberto Martinez from the Board of Directors

Rosen Law Firm Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action

What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation

Analysts update estimates

Bragar Eagel & Squire, P.C. Reminds Investors Deadline on the Class Action Lawsuit Against Celsion Corporation

Third quarter 2020 earnings released: US$0.24 loss per share

Earnings beat expectations, revenue disappoints

Celsion slips 4% on Q3 earnings miss

Celsion Corporation to Report Q3, 2020 Results on Nov 16, 2020

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Celsion Corporation and Encourages Investors to Contact the Firm

New 90-day low: US$0.52

Celsion Corporation Provides an Update on the Ongoing Data Analysis from Its Phase III Optima Study with Thermodox® Plus Radiofrequency Ablation